PCVX - Vaxcyte Inc Debt to Book Capitalization Ratio

Vaxcyte, Inc. (PCVX) develops cutting-edge drugs against dangerous bacteria, utilizing a unique synthesis technology to enhance vaccine efficacy. The business currently relies on external contractors for testing, which creates risks for release timelines. This daily price chart for the stock with the 0.04 metric reflects the dynamics of a biotech company that supplies innovative pneumococcal protection tools to public and private medical centers.

PCVX (SutroVax) Debt to Book Value history from 07/04/2022 to 10/27/2026

Metric breakdowns and analytics for Vaxcyte Inc (PCVX)

- price and consensus price forecast:

Stock Price Vaxcyte, Inc.|PCVX - Analyst Consensus Forecast

- market capitalization data:

Market Value SutroVax|PCVX - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Vaxcyte|PCVX - Company Net Assets|Market Capitalization to Book Value Ratio vaxcyte.com|PCVX - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Vaxcyte, Inc.|PCVX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Vaxcyte Corp|PCVX - Company Total Debt Obligations|Debt to Book Capitalization Ratio SutroVax

Summary company analytics:PCVX - Vaxcyte, Inc.

Developing innovative vaccines requires significant investment in scientific expertise, making debt load control critically important. By analyzing the ratio of total liabilities to book capitalization, an investor assesses the share of borrowed capital within the asset structure to determine the level of investment protection against credit risks. A decrease in this metric confirms the financial stability of Vaxcyte, Inc. (PCVX) and minimizes the probability of portfolio devaluation during market turmoil.

Competitors of Vaxcyte, Inc.